Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
Marek Hus(Medical University of Lublin), Anna Dmoszyńska(1 Military Clinical Hospital with Outpatient Clinic), Marta Szostek(Jagiellonian University), Dariusz Jawniak, Grzegorz Helbig(Medical University of Silesia), Justyna Kozińska(Medical University of Lublin), Maria Cioch(Medical University of Lublin), Dariusz Woszczyk(University of Opole), Marta Morawska(Lublin Oncology Center), Wojciech Legieć, Piotr Waciński(Medical University of Lublin), Andrzej Pluta(Lublin Oncology Center), Norbert Grząśko(Lublin Oncology Center)
Cited by 62
Related Papers
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia
|New England Journal of Medicine|2004|921
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2007|556
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70